Bioanalysis of meningococcal vaccines

Bioanalysis

Volumn 2, Issue 2, 2010, Pages 343-361

  Ravenscroft, Neil ^a   Wheeler, Jun X ^b   Jones, Christopher ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; GLYCOCONJUGATE; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; RECOMBINANT VACCINE; OUTER MEMBRANE PROTEIN; POLYSACCHARIDE; VACCINE;

ARTICLE; CONJUGATION; DRUG ANALYSIS; DRUG DESIGN; DRUG FORMULATION; DRUG IDENTIFICATION; DRUG STRUCTURE; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOGENICITY; MOLECULAR SIZE; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; QUALITY CONTROL; ANIMAL; CARBOHYDRATE ANALYSIS; CHEMISTRY; IMMUNOLOGY; MOLECULAR GENETICS; REVIEW;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; CARBOHYDRATE SEQUENCE; HUMANS; MENINGOCOCCAL VACCINES; MOLECULAR SEQUENCE DATA; POLYSACCHARIDES; VACCINES, CONJUGATE;

EID: 79952516010     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.181     Document Type: Article

References (97)

1. Plotkin SL, Plotkin SA. A short history of vaccination. In: Vaccines 4th Edition. Plotkin SA, Orenstein W, Offit PA (Eds). Elsevier-Saunders, PA, USA, 1-15 (2004).
2. McLeod CM, Hodges RC, Heidelberger M, Bernhardt WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 82, 445-465 (1945).
3. Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. New Engl. J. Med. 319(15), 964-971 (1988).
4. Avery OT, Goebel WF. Chemo-immunological studies on conjugated carbohydrate-proteins: V. The immunological specifity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein. J. Exp. Med. 54, 437-447 (1931).
5. Robbins JB, Schneerson R, Szu SC, et al. Prevention of invasive bacterial diseases by immunization with polysaccharide-protein conjugates. Curr. Top. Microbiol. Immunol. 146, 169-180 (1989).
6. Robbins JB, Schneerson R, Anderson P, Smith DH. The 1996 Albert Lasker medical research awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide-based vaccines. JAMA 276(14), 1181-1185 (1996). (Pubitemid 26329749)
7. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev. Vaccines 8(7), 851-861 (2009).
8. Darkes MJ, Plosker GL. Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection. Paediatr. Drugs 4(9), 609-630 (2002). (Pubitemid 34983406)
9. LaForce MF, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 27(Suppl. 2), B13-B19 (2009).
10. Dinleyici EC, Yargic ZA. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Exp. Rev. Vaccines 8(8), 977-986 (2009).
11. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 27(Suppl. 2), B51-B63, (2009).
12. Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 27(Suppl. 2), B20-B29 (2009).
13. Wilder-Smith A. Meningococcal vaccine in travelers. Curr. Opin. Infect. Dis. 20(5), 454-460 (2007). (Pubitemid 47359640)
14. Suker J, Feavers IM, Corbel MJ, Jones C, Bolgiano B. Control and lot release of meningococcal group C conjugate vaccines. Expert Rev. Vaccines 3(5), 533-540 (2004). (Pubitemid 39440829)
15. Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines. Vaccine 27(Suppl. 2), B30-B41 (2009).
16. Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2(8346), 355-357 (1983). (Pubitemid 13028927)
17. Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27(Suppl. 2), B3-B12 (2009).
18. Lewis S, Sadarangani M, Hoe JC, Pollard AJ. Challenges and progress in the development of a serogroup B meningococcal vaccine. Expert Rev. Vaccines 8(6), 729-745 (2009).
19. Feavers IM, Pizza M. Meningococcal protein antigens and vaccines. Vaccine 27(Suppl. 2), B42-B50 (2009).
20. Granoff DM, Feavers IM, Borrow R. Meningococcal vaccines. In: Vaccines 4th Edition. Plotkin SA, Orenstein W, Offit PA (Eds). Elsevier-Saunders, PA, USA, 959-987 (2004).
21. Requirements for meningococcal polysaccharide vaccine. WHO Tech. Rep. Series 658, 174-184 (1981).
22. Frasch CE. Production and control of Neisseria meningitidis vaccines. Adv. Biotechnol. Processes 13, 123-145 (1990).
23. Jones C, Currie F. Control of components of bacterial polysaccharide vaccines by physical methods. Biologicals 1, 41-47 (1991).
24. European Department for the Quality of Medicines. Biological beyond 2000, challenges for quality standards in an evolving field. Presented at: EDQM/European Pharmacopoeia Meeting. PHARMEUROPA Special Issue. BIO-2000 (2000).
25. Ravenscroft N, D'Ascenzi S, Proietti D, Norelli F, Costantino P. Physicochemical characterisation of the oligosaccharide component of vaccines. Dev. Biol. (Basel) 103, 35-47 (2000).
26. Metz B, van den Dobbelsteen G, van Els C, et al. Quality-control issues and approaches in vaccine development. Expert Rev. Vaccines 8(2), 227-238 (2009).
27. Frasch CE. Preparation of bacterial polysaccharide-protein conjugates: analytical and manufacturing challenges. Vaccine 27(46), 6468-6470 (2009).
28. Lemercinier X, Jones C. Full 1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from Neisseria meningitidis used in vaccine production. Carbohydr. Res. 296, 83-96 (1996). (Pubitemid 27008331)
29. Jones C, Lemercinier X. Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture. J. Pharm. Biomed. Anal. 30(4), 1233-1247 (2002). (Pubitemid 35284335)
30. Gudlavalleti SK, Szymanski CM, Jarrell HC, Stephens DS. In vivo determination of Neisseria meningitidis serogroup A capsular polysaccharide by whole cell high-resolution magic angle spinning NMR spectroscopy. Carbohydr. Res. 341(4), 557-562 (2006). (Pubitemid 43202157)
31. Jones C, Ravenscroft N. NMR assays for carbohydrate-based vaccines. In: NMR Spectroscopy in Pharmaceutical Analysis. Holtzgrabe U, Wawer I, Diehl B (Eds). Elsevier, Oxford, UK, 341-368 (2008).
32. Xu Q, Klees J, Teyral J, et al. Quantitative nuclear magnetic resonance analysis and characterization of the derivatized Haemophilus influenzae type b polysaccharide intermediate for PedvaxHIB. Anal. Biochem. 337(2), 235-245 (2005). (Pubitemid 40187250)
33. Chen PS, Toribara TY, Warner H. Microdetermination of phosphorus. Anal. Chem. 28(11), 1756-1758 (1956).
34. Svennerholm L. Quantitative estimation of sialic acid. a colorimetric resorcinol-hydrochloric acid method. Biochim. Biophys. Acta. 24, 604-611 (1957).
35. Hestrin S. The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application. J. Biol. Chem. 180, 249-261 (1949).
36. Ricci S, Bardotti A, D'Ascenzi S, Ravenscroft N. Development of a new method for the quantitative analysis of extracellular polysaccharide of Neisseria meningitidis serogroup A by use of high-performance anion-exchange chromatography with pulsed-amperometric detection. Vaccine 19(15-16), 1989-1997 (2001). (Pubitemid 32178347)
37. Kao G, Tsai CM. Quantification of O-acetyl, N-acetyl and phosphate groups and determination of the extent of O-acetylation in bacterial vaccine polysaccharides by high-performance anion-exchange chromatography with conductivity detection (HPAEC-CD). Vaccine 22(3-4), 335-344 (2004). (Pubitemid 37510263)
38. Lamb DH, Lei QP, Hakim N, Rizzo S, Cash P. Determination of meningococcal polysaccharides by capillary zone electrophoresis. Anal. Biochem. 338(2), 263-269 (2005). (Pubitemid 40312590)
39. Li Y, Lander R, Manger W, Lee A. Determination of lipid profile in meningococcal polysaccharide using reversed-phase liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 804(2), 353-358 (2004). (Pubitemid 38481711)
40. Bednar B, Hennessey JP Jr. Molecular size analysis of capsular polysaccharide preparations from Streptococcus pneumonia. Carbohydr. Res. 243(1), 115-130 (1993). (Pubitemid 23131029)
41. von Hunolstein C, Parisi L, Bottaro D. Simple and rapid technique for monitoring the quality of meningococcal polysaccharides by high performance size-exclusion chromatography. J. Biochem. Biophys. Methods 56(1-3), 291-296 (2003). (Pubitemid 36776608)
42. Lindberg AA. Glycoprotein conjugate vaccines. Vaccine 17(Suppl. 2), S28-S36 (1999). (Pubitemid 29457533)
43. Fukasawa LO, Gorla MC, Schenkman RP, et al. Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate.Vaccine 17(23-24), 2951-2958 (1999). (Pubitemid 29366974)
44. Pérez AE, Dickinson FO, Banderas F, et al. Safety and preliminary immunogenicity of MenC/P64k, a meningococcal serogroup C conjugate vaccine with a new recombinant carrier. FEMS Immunol. Med. Microbiol. 46(3), 386-392 (2006).
45. Lees A, Nelson BL, Mond JJ. Activation of soluble polysaccharides with 1-cyano-4- dimethylaminopyridinium tetrafluroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine 14, 190-198 (1996). (Pubitemid 26099045)
46. Lee CH, Kuo WC, Beri S, et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine 27(5), 726-732 (2009).
47. Costantino P, Norelli F, Giannozzi A, et al. Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines, Vaccine 17(9-10), 1251-1263 (1999). (Pubitemid 29132960)
48. Ravenscroft N, Averani G, Bartoloni A, et al. Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines. Vaccine 17(22), 2802-2816 (1999). (Pubitemid 29323006)
49. Bardotti A, Averani G, Berti F, et al. Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases. Vaccine 26(18), 2284-2296 (2008).
50. Bartoloni A, Norelli F, Ceccarini C, Rappuoli R, Costantino P. Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide. Vaccine 13(5), 463-470 (1995).
51. World Health Organization. Recommendations for the production and control of meningococcal group C conjugate vaccines. WHO Tech. Rep. Series 924, 102-128 (2004).
52. Silveira IA, Bastos RC, Neto MS, et al. Characterization and immunogenicity of meningococcal group C conjugate vaccine prepared using hydrazide-activated tetanus toxoid. Vaccine 25(41), 7261-7270 (2007). (Pubitemid 47464664)
53. Cai X, Lei QP, Lamb DH, et al. LC/MS characterization of meningococcal depolymerized polysaccharide group C reducing endgroup and internal repeating unit. Anal. Chem. 76(24), 7387-7390 (2004). (Pubitemid 39658012)
54. Gudlavalleti SK, Lee CH, Norris SE, Paul-Satyaseela M, Vann WF, Frasch CE. Comparison of Neisseria meningitidis serogroup W-135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide. Vaccine 25(46), 7972-7980 (2007). (Pubitemid 47632976)
55. Bardotti A, Averani G, Berti F, et al. Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines against Neisseria meningitidis groups Y and W-135. Vaccine 23(16), 1887-1899 (2005). (Pubitemid 40289059)
56. World Health Organization. Recommendations for the production and control of Haemophilus influenza type b conjugate vaccines. WHO Tech. Rep. Series 897, 27-56 (2000).
57. World Health Organization. Recommendations for the production and control of meningococcal group C conjugate vaccines. WHO Tech. Report Series 924, 102-128 (2004).
58. Proietti D, Abballe F, Bardotti A, Ricci S, D'Ascenzi S. Chromatographic characterization of bacterial oligosaccharides by anion exchange profiles combining different detection techniques, Glycoconj. J. 22(4-6), 232 (2005)
59. Tomei M, Pacella G, Campa C, D'Ascenzi S. Determination of size distributions of meningococcal oligosaccharides. P142. Presented at: 8th Carbohydrate Bioengineering Meeting, Ischia, Italy, May 10-13 2009.
60. D'Ambra AJ, Baugher JE, Concannon PE, Pon PA, Michon F. Direct and indirect methods for molar-mass analysis of fragments of the capsular polysaccharides of Haemophilus influenzae type b. Anal. Biochem. 250(2), 228-236 (1997). (Pubitemid 27319101)
61. Ravenscroft N. The application of NMR spectroscopy to track the industrial preparation of polysaccharide and derived glycoconjugate vaccines. Pharmeuropa Biologicals Beyond 2000 (Special issue), 131-144 (2000).
62. Hsieh CL. Characterization of saccharide- CRM197 conjugate vaccines, Dev. Biol. (Basel) 103, 93-104 (2000).
63. Jones C, Lemercinier X, Crane DT, Gee CK, Austin S. Spectroscopic studies of the structure and stability of glycoconjugate vaccines. Dev. Biol. (Basel) 103, 121-136 (2000).
64. Lei QP, Shannon AG, Heller RK, Lamb DH. Quantification of free polysaccharide in meningococcal polysaccharide-diphtheria toxoid conjugate vaccines. Dev. Biol. (Basel) 103, 259-264 (2000).
65. Ho MM, Bolgiano B, Corbel MJ. Assessment of the stability and immunogenicity of meningococcal oligosaccharide C-CRM197 conjugate vaccines. Vaccine 19(7-8), 716-725 (2000).
66. Lamb DH, Summa L, Lei QP, Duval G, Adam O. Determination of free carrier protein in protein-polysaccharide conjugate vaccines by micellar electrokinetic chromatography. J. Chromatogr. A 894(1-2), 311-318 (2000).
67. Ravenscroft N, Chen J, Hearshaw M, et al. The application of physicochemical methods of analysis to the development of conjugate vaccines against meningococcal group A bacteria. In: Proceedings of the 15th International Pathogenic Neisseria Conference. (2006).
68. Jumel K, Ho MM, Bolgiano B. Evaluation of meningococcal C oligosaccharide conjugate vaccines by size-exclusion chromatography/multi-angle laser light scattering, Biotechnol. Appl. Biochem. 36(Part 3), 219-226 (2002). (Pubitemid 36009071)
69. Lei QP, Lamb DH, Shannon AG, et al. Quantification of residual EDU (N-ethyl-N′- (dimethylaminopropyl)carbodiimide (EDC) hydrolyzed urea derivative) and other residual by LC-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 813(1-2), 103-112 (2004). (Pubitemid 39535435)
70. Ho MM, Mawas F, Bolgiano B, et al. Physicochemical and immunological examination of the thermal stability of tetanus toxoid conjugate vaccines. Vaccine 20(29-30), 3509-3522 (2002). (Pubitemid 35248075)
71. Helting TB, Guthorlein G, Blackkolb F, Ronneberger H. Serotype determinant protein of Neisseria meningitides. Large scale preparation by direct detergent treatment of the bacterial cells. Acta Pathol. Microbiol. Scand. C 89(2).69-78 (1981). (Pubitemid 11145704)
72. Van Alphen L, van den Dobbelsteen G. Meningococcal B vaccine development and evaluation of efficacy. Human Vaccine 4(2), 158-161 (2008). (Pubitemid 351881185)
73. Vipond C, Wheeler JX, Jones C, Feavers IM, Suker J. Characterisation of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry. Human Vaccines 1(2), 80-84 (2005).
74. Post DM, Zhang D, Eastvold JS, Teghanemt A, Gibson BW, Weiss JP. Biochemical and functional characterization of membrane blebs purified from Neisseria meningitidis serogroup B. J. Biol. Chem. 280(46), 38383-38394 (2005). (Pubitemid 43853735)
75. Finney M, Vaughan T, Taylor S, et al. Characterization of the key antigenic components and preclinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Human Vaccine 4(1), 23-30 (2008). (Pubitemid 351785257)
76. Mignogna G, Giorgi A, Stefanelli P, et al. Inventory of the proteins in Neisseria meningitidis serogroup B strain MC58. J. Proteome Res. 4(4), 1361-1370 (2005). (Pubitemid 41208693)
77. Ferrari G, Garaguso I, Adu-Bobie J, et al. Outer membrane vesicles from group B Neisseria meningitidis d gna33 mutant. proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics 6(6), 1856-1866 (2006).
78. Vipond C, Suker J, Jones C, Tang C, Feavers IM, Wheeler JX. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. Proteomics 6(11), 3400-3413 (2006). (Pubitemid 43886156)
79. Uli L, Castellanos-Serra L, Betancourt L, et al. Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis.
80. Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 6(11), 3389-3399 (2006).
81. Vaughan TE, Skipp PJ, O'Connor CD, et al. Proteomic analysis of Neisseria lactamica and Neisseria meningitidis outer membrane vesicle vaccine antigens. Vaccine 24(25), 5277-5293 (2006). (Pubitemid 43818201)
82. Williams JN, Skipp PJ, Humphries HE, Christodoulides M, O'Connor CD, Heckels JE. Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant. Infect Immun. 75(3), 1364-1372 (2007). (Pubitemid 46385830)
83. Gil J, Betancourt LZ, Sardiñas G, et al. Proteomic study via a nongel based approach of meningococcal outer membrane vesicle vaccine obtained from strain CU385. A road map for discovering new antigens. Human Vaccine 5(5), 347-356 (2009).
84. Frasch CE, van Alphen L, Holst J, Poolman JT, Rosenqvist E. Outer membrane protein vesicle vaccines from meningococcal disease. In: Meningococcal Vaccines: Methods and Protocols Pollard AJ, Maiden MC (Eds). Humana Press, NJ, USA 66, 81-107 (2001).
85. Wedege E, Høiby EA, Rosenqvist E, Bjune G. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccines and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect. Immun. 66(7), 3223-3231 (1998). (Pubitemid 28303120)
86. Russell JE, Urwin R, Gray SJ, Fox AJ, Feavers IM, Maiden MC. Molecular epidemiology of meningococcal disease in England and Wales 1975-1995, before the introduction of serogroup C conjugate vaccine. Microbiology 154(Part 4), 1170-1177 (2008). (Pubitemid 351736273)
87. Williams TL, Luna L, Guo Z, et al. Quantification of influenza virus hemagglutinins in complex mintures using isotope dilution tandem mass spectrometry. Vaccine 26(20), 2510-2520 (2008).
88. Wheeler JX, Vipond C, Feavers IM. Exploring the proteome of meningococcal outer membrane vesicle vaccines. Proteomics Clin. Appl. 1(9), 1198-1210 (2007).
89. Mendum TA, Newcombe J, McNeilly CL, McFadden J. Towards the immnuoproteme of Neisseria meningitidis. PLoS One 4(6), e5940 (2009).
90. Williams JN, Skipp PJ, O'Connor CD, Christodoulides M, Heckels JE. Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates. Infect. Immun. 77(11), 5080-5089 (2009).
91. Perez O, lastre M, Lapinet J, et al. Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine. Infect. Immun. 69(7), 4502-4508 (2001).
92. Hou VC, Koeberling O, Welsch JA, Granoff DM. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J. Infect Dis. 19(4), 580-590 (2005). (Pubitemid 41099306)
93. Koeberling O, Giuntini S, Seubert A, Granoff DM. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin. Vaccine Immunol. 16(2), 156-162 (2009).
94. Jacobsson S, Hedberg ST, Mölling P, et al. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 27(10), 1579-1584 (2009).
95. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA 103(29), 10834-10839 (2006). (Pubitemid 44148381)
96. Recommendations to assure the quality, safety and efficacy of group A meningococcal conjugate vaccines www.who.int/biologicals/publications/trs/areas/ vaccines/meningococcal/MenA%20 Final%20BS204102.Nov.06.pdf
97. WHO. Meningitis Fact sheet N 141. Revised May 2003 www.who.int/ mediacentre/factsheets/2003/fs141/en/